A clinical trial of edrecolomab, interleukin-2 and GM-CSF in patients with advanced colorectal cancer

  • Authors:
    • Walter Fiedler
    • William Kruger
    • Eckart Laack
    • Thorsten Mende
    • Gabi Vohwinkel
    • Dieter K. Hossfeld
  • View Affiliations

  • Published online on: March 1, 2001     https://doi.org/10.3892/or.8.2.225
  • Pages: 225-231
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Immunological effector mechanisms of monoclonal antibodies such as antibody-dependent cytotoxicity can be augmented by the cytokines granulocyte-macrophage colony-stimulating factor (GM-CSF) or interleukin-2 (IL-2). Therefore twelve patients with metastatic colorectal cancer were treated with 300 μg GM-CSF and 6 million units IL-2 subcutaneously daily from day 1 to 10 followed by a three week rest period. Of the edrecolomab 400 mg was given on day 3 of the first cycle. The dose was reduced to 150 mg on subsequent cycles. A maximum of four cycles was administered. Toxicity was manageable on an outpatient basis. No partial or complete responses were observed in these 12 patients. Median time to treatment failure was 67 days and median survival 287 days. Immunological parameters were monitored throughout the study.

Related Articles

Journal Cover

March-April 2001
Volume 8 Issue 2

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Fiedler W, Kruger W, Laack E, Mende T, Vohwinkel G and Hossfeld DK: A clinical trial of edrecolomab, interleukin-2 and GM-CSF in patients with advanced colorectal cancer. Oncol Rep 8: 225-231, 2001
APA
Fiedler, W., Kruger, W., Laack, E., Mende, T., Vohwinkel, G., & Hossfeld, D.K. (2001). A clinical trial of edrecolomab, interleukin-2 and GM-CSF in patients with advanced colorectal cancer. Oncology Reports, 8, 225-231. https://doi.org/10.3892/or.8.2.225
MLA
Fiedler, W., Kruger, W., Laack, E., Mende, T., Vohwinkel, G., Hossfeld, D. K."A clinical trial of edrecolomab, interleukin-2 and GM-CSF in patients with advanced colorectal cancer". Oncology Reports 8.2 (2001): 225-231.
Chicago
Fiedler, W., Kruger, W., Laack, E., Mende, T., Vohwinkel, G., Hossfeld, D. K."A clinical trial of edrecolomab, interleukin-2 and GM-CSF in patients with advanced colorectal cancer". Oncology Reports 8, no. 2 (2001): 225-231. https://doi.org/10.3892/or.8.2.225